Advertisement
Canada markets closed

  • S&P/TSX

    21,639.10
    -59.01 (-0.27%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CAD/USD

    0.7281
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     

  • Bitcoin CAD

    90,986.91
    +981.46 (+1.09%)
     

  • CMC Crypto 200

    1,403.64
    -14.23 (-1.00%)
     

  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     

  • RUSSELL 2000

    2,006.16
    -32.75 (-1.61%)
     

  • 10-Yr Bond

    4.2130
    -0.0250 (-0.59%)
     

  • NASDAQ

    17,688.88
    +21.32 (+0.12%)
     

  • VOLATILITY

    12.66
    +0.72 (+6.03%)
     

  • FTSE

    8,146.86
    -16.81 (-0.21%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

  • CAD/EUR

    0.6798
    +0.0024 (+0.35%)
     

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

Business Wire
·1 min read

NEW YORK & HERZLIYA, Israel, May 22, 2024--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City.

This prestigious event will bring together senior management teams from leading cannabis companies including InterCure CEO Alex Rabinovitch, to engage in panel discussions, fireside chats, and one-on-one meetings. For more information about the event please refer to the following link:

https://www.canaccordgenuity.com/capital-markets/events-and-conferences/cg-8th-annual-global-cannabis-conference/

ADVERTISEMENT

About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: http://www.intercure.co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522762595/en/

Contacts

InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co